Communiqués NeuroSense Therapeutics Ltd.

Actions

NRSN

IL0011809592

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 07/06/2024			Varia. 5j.	Varia. 1 janv.
1,1 ^USD	-3,51 %		+1,85 %	+40,13 %

14/05	NeuroSense s'associe à PhaseV pour un essai clinique sur le traitement de la SLA -- Les actions sont en hausse	MT
07/05	NeuroSense annonce une nouvelle analyse positive des données de l'essai clinique PARADIGM démontrant un ralentissement statistiquement significatif de la progression de la maladie chez les patients à haut risque de la SLA	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 - Form 6-K	28/05	PU
NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JUNE 27, 2024 - Form 6-K	23/05	PU
NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit	20/05	PR
NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning	14/05	PR
NeuroSense Therapeutics : Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning - Form 6-K	14/05	PU
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients	07/05	PR
NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease	22/04	PR
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting	19/04	AQ
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024	15/04	AQ
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement	11/04	PR
NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics	09/04	PR
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	08/04	AQ
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update	05/04	PR
NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial	21/02	PR
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule	07/02	PR
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts	09/01	PR
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement	27/12	PR
NeuroSense Reports New Data, Statistically Significant Clinical Efficacy in Phase 2b ALS Trial	15/12	AQ
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial	14/12	PR
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability and Secondary Clinical Efficacy Endpoints	06/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués NeuroSense Therapeutics Ltd.

Actions

NRSN

IL0011809592

Communiqués

Filtres